TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preventing Overweight Using Novel Dietary Strategies (Pounds Lost)
Brief Summary: The purpose of this study is to test the effectiveness for weight loss and weight maintenance of four diets differing in macronutrient composition: moderate in fat (40 percent energy) with two different protein levels (15 percent and 25 percent), and low in fat (20 percent energy), also with 15 percent and 25 percent protein levels. The study is only accepting participants in the Boston, Massachusetts or Baton Rouge, Louisiana area. For further enrollment information in Boston or Baton Rouge, see Eligibility Criteria or Design Narrative.


Options:
A: Intervention Type: BEHAVIORAL; Name: Four Diets Differing in Macronutrient Composition; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Diets Low in Saturated Fat; Assigned to Arm(s): N/A
B: Arm Label: 20% protein hypocaloric diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Weight loss interventional study with 20% protein-diet | Arm Label: 27% protein hypocaloric diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Weight loss interventional study with 27% protein-diet | Arm Label: 35% protein hypocaloric diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Weight loss interventional study with 35% protein-diet | Intervention Type: BEHAVIORAL; Name: Weight loss interventional study with 20% protein-diet; Assigned to Arm(s): 20% protein hypocaloric diet | Intervention Type: BEHAVIORAL; Name: Weight loss interventional study with 27% protein-diet; Assigned to Arm(s): 27% protein hypocaloric diet | Intervention Type: BEHAVIORAL; Name: Weight loss interventional study with 35% protein-diet; Assigned to Arm(s): 35% protein hypocaloric diet
C: Arm Label: Vegan Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Intervention Meetings, Behavioral: Physical Activity, Behavioral: Podcasts/Mailings | Arm Label: Omnivorous (Omni) Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Intervention Meetings, Behavioral: Physical Activity, Behavioral: Podcasts/Mailings | Intervention Type: BEHAVIORAL; Name: Dietary Intervention Meetings; Assigned to Arm(s): Omnivorous (Omni) Diet, Vegan Diet | Intervention Type: BEHAVIORAL; Name: Physical Activity; Assigned to Arm(s): Omnivorous (Omni) Diet, Vegan Diet | Intervention Type: BEHAVIORAL; Name: Podcasts/Mailings; Assigned to Arm(s): Omnivorous (Omni) Diet, Vegan Diet
D: Arm Label: Enhanced Portfolio plus structured exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced portfolio plus structured exercise | Arm Label: High fiber diet plus routine exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: High fiber diet plus routine exercise | Intervention Type: BEHAVIORAL; Name: Enhanced portfolio plus structured exercise; Assigned to Arm(s): Enhanced Portfolio plus structured exercise | Intervention Type: BEHAVIORAL; Name: High fiber diet plus routine exercise; Assigned to Arm(s): High fiber diet plus routine exercise

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preventing Overweight Using Novel Dietary Strategies (Pounds Lost)
Brief Summary: The purpose of this study is to test the effectiveness for weight loss and weight maintenance of four diets differing in macronutrient composition: moderate in fat (40 percent energy) with two different protein levels (15 percent and 25 percent), and low in fat (20 percent energy), also with 15 percent and 25 percent protein levels. The study is only accepting participants in the Boston, Massachusetts or Baton Rouge, Louisiana area. For further enrollment information in Boston or Baton Rouge, see Eligibility Criteria or Design Narrative.


Options:
A: Intervention Type: BEHAVIORAL; Name: Four Diets Differing in Macronutrient Composition; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Diets Low in Saturated Fat; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: diet, sodium-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: alcohol drinking; Assigned to Arm(s): N/A
C: Arm Label: High MUFA diet; Type: EXPERIMENTAL; Interventions: Other: High-MUFA diet | Arm Label: High CHO diet; Type: ACTIVE_COMPARATOR; Interventions: Other: High-CHO diet | Intervention Type: OTHER; Name: High-MUFA diet; Assigned to Arm(s): High MUFA diet | Intervention Type: OTHER; Name: High-CHO diet; Assigned to Arm(s): High CHO diet
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Low-fat, low-Glycemic Index, vegan diet | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Low-fat, low-Glycemic Index, vegan diet | Intervention Type: BEHAVIORAL; Name: Low-fat, low-Glycemic Index, vegan diet; Assigned to Arm(s): 1, 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preventing Overweight Using Novel Dietary Strategies (Pounds Lost)
Brief Summary: The purpose of this study is to test the effectiveness for weight loss and weight maintenance of four diets differing in macronutrient composition: moderate in fat (40 percent energy) with two different protein levels (15 percent and 25 percent), and low in fat (20 percent energy), also with 15 percent and 25 percent protein levels. The study is only accepting participants in the Boston, Massachusetts or Baton Rouge, Louisiana area. For further enrollment information in Boston or Baton Rouge, see Eligibility Criteria or Design Narrative.


Options:
A: Arm Label: Omega 3 recipient arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Omega 3 Fish Oil supplements | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Omega 3 Fish Oil supplements; Assigned to Arm(s): Omega 3 recipient arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Synbiotic; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Synbiotic | Arm Label: Maltodextrin; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Maltodextrin | Intervention Type: DIETARY_SUPPLEMENT; Name: Synbiotic; Assigned to Arm(s): Synbiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: Maltodextrin; Assigned to Arm(s): Maltodextrin
C: Intervention Type: BEHAVIORAL; Name: Four Diets Differing in Macronutrient Composition; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Diets Low in Saturated Fat; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Randomized, 6-Week, Parallel-Group Design Clinical Trial to Assess Safety and Efficacy of Asacol 4.8 g/Day (800 mg Tablet) Versus Asacol 2.4 g/Day (400 mg Tablet) for the Treatment of Moderately Active Ulcerative Colitis
Brief Summary: This study is a prospective clinical study to evaluate the safety and efficacy of two different doses of Asacol for the treatment of moderately active ulcerative colitis. In addition, a new tablet formulation will be evaluated at one of the two doses.


Options:
A: Arm Label: Asacol 2.4 g/day; Type: ACTIVE_COMPARATOR; Interventions: Drug: Asacol 400 mg (mesalamine) | Arm Label: Asacol 4.8 g/day; Type: EXPERIMENTAL; Interventions: Drug: Asacol 800 mg (mesalamine) | Intervention Type: DRUG; Name: Asacol 800 mg (mesalamine); Assigned to Arm(s): Asacol 4.8 g/day | Intervention Type: DRUG; Name: Asacol 400 mg (mesalamine); Assigned to Arm(s): Asacol 2.4 g/day
B: Arm Label: Dex 21-P; Type: EXPERIMENTAL; Interventions: Drug: Dex 21-P | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Dex 21-P; Assigned to Arm(s): Dex 21-P | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: SPD476 (mesalazine); Assigned to Arm(s): N/A
D: Arm Label: LT-02 Dose 1; Type: EXPERIMENTAL; Interventions: Drug: LT-02 | Arm Label: LT-02 Dose 2; Type: EXPERIMENTAL; Interventions: Drug: LT-02 | Arm Label: LT-02 Dose 3; Type: EXPERIMENTAL; Interventions: Drug: LT-02 | Arm Label: Sugar pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: LT-02; Assigned to Arm(s): LT-02 Dose 1, LT-02 Dose 2, LT-02 Dose 3 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Sugar pill

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer.
Brief Summary: The purpose of this study is to evaluate safety, efficacy (including quality of life), and pharmacokinetics of BAY43-9006 when added to Best Supportive Care in patients with unresectable and/or metastatic renal cell cancer, who have received one prior systemic regimen for advanced disease.


Options:
A: Arm Label: Experimental Arm; Type: EXPERIMENTAL; Interventions: Drug: Cabozantinib, Biological: Nivolumab, Biological: Ipilimumab | Arm Label: Control Arm; Type: ACTIVE_COMPARATOR; Interventions: Biological: Nivolumab, Biological: Ipilimumab, Drug: Cabozantinib-matched placebo | Intervention Type: DRUG; Name: Cabozantinib; Assigned to Arm(s): Experimental Arm | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Control Arm, Experimental Arm | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Control Arm, Experimental Arm | Intervention Type: DRUG; Name: Cabozantinib-matched placebo; Assigned to Arm(s): Control Arm
B: Arm Label: Sorafenib (Nexavar, BAY43-9006); Type: EXPERIMENTAL; Interventions: Drug: Sorafenib (Nexavar, BAY43-9006) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sorafenib (Nexavar, BAY43-9006); Assigned to Arm(s): Sorafenib (Nexavar, BAY43-9006) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Cediranib (AZD2171) Treatment; Type: EXPERIMENTAL; Interventions: Drug: AZD2171 | Intervention Type: DRUG; Name: AZD2171; Assigned to Arm(s): Cediranib (AZD2171) Treatment
D: Arm Label: placebo arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: pazopanib arm; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): pazopanib arm | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo arm

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer.
Brief Summary: The purpose of this study is to evaluate safety, efficacy (including quality of life), and pharmacokinetics of BAY43-9006 when added to Best Supportive Care in patients with unresectable and/or metastatic renal cell cancer, who have received one prior systemic regimen for advanced disease.


Options:
A: Intervention Type: DRUG; Name: Sutent; Assigned to Arm(s): N/A
B: Arm Label: Sorafenib (Nexavar, BAY43-9006); Type: EXPERIMENTAL; Interventions: Drug: Sorafenib (Nexavar, BAY43-9006) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sorafenib (Nexavar, BAY43-9006); Assigned to Arm(s): Sorafenib (Nexavar, BAY43-9006) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: SU011248 (sunitinib); Type: EXPERIMENTAL; Interventions: Drug: SU011248 (sunitinib) | Intervention Type: DRUG; Name: SU011248 (sunitinib); Assigned to Arm(s): SU011248 (sunitinib)
D: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon-alfa | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SU011248 | Intervention Type: DRUG; Name: Interferon-alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: SU011248; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Duloxetine Versus Escitalopram and Placebo in the Treatment of Patients With Major Depression
Brief Summary: The purposes of this study are to determine:

* The safety of duloxetine and any side effects that might be associated with it.
* How duloxetine compares to escitalopram and placebo (an inactive ingredient)


Options:
A: Intervention Type: DRUG; Name: Quetiapine fumarate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A
B: Arm Label: Desvenlafaxine succinate sustained-release 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR) | Arm Label: Desvenlafaxine succinate sustained-release 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Duloxetine 60mg; Type: OTHER; Interventions: Drug: Duloxetine 60 mg/day | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release (DVS SR); Assigned to Arm(s): Desvenlafaxine succinate sustained-release 50 mg | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release (DVS SR); Assigned to Arm(s): Desvenlafaxine succinate sustained-release 100 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Duloxetine 60 mg/day; Assigned to Arm(s): Duloxetine 60mg
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Vortioxetine 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine (Lu AA21004) | Arm Label: Duloxetine 60 mg; Type: OTHER; Interventions: Drug: Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Vortioxetine (Lu AA21004); Assigned to Arm(s): Vortioxetine 5 mg | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine 60 mg
D: Intervention Type: DRUG; Name: duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: escitalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of Depression in At-Risk Adolescents
Brief Summary: This study examines the impact of a group cognitive behavioral program aimed at preventing depressive disorders and symptoms in adolescents at risk for developing depression.


Options:
A: Arm Label: Prevention programme; Type: EXPERIMENTAL; Interventions: Behavioral: Prevention programme | Arm Label: Control (treatment as usual); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Prevention programme; Assigned to Arm(s): Prevention programme
B: Arm Label: 1= Cognitive behavioral prevention of depression program; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive-behavioral prevention program | Arm Label: 2 = Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: BEHAVIORAL; Name: Cognitive-behavioral prevention program; Assigned to Arm(s): 1= Cognitive behavioral prevention of depression program | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): 2 = Usual care
C: Intervention Type: BEHAVIORAL; Name: Screening (Behavior); Assigned to Arm(s): N/A
D: Arm Label: Mood monitoring; Type: EXPERIMENTAL; Interventions: Device: Mobile Tracking Young People's Experiences (mobiletype) | Arm Label: Comparison monitoring program; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Mobile Tracking Young People's Experiences (mobiletype); Assigned to Arm(s): Mood monitoring

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Clinical Trial With Caelyx Mono-Chemotherapy in Patients With Advanced Mycosis Fungoides Stage IIb, IVa and IVb With or Without Previous Chemotherapy
Brief Summary: RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin, use different ways to stop cancer cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of liposomal doxorubicin in treating patients who have stage IIB, stage IVA, or stage IVB recurrent or refractory mycosis fungoides.


Options:
A: Arm Label: lenalidomide; Type: EXPERIMENTAL; Interventions: Drug: lenalidomide | Arm Label: Observation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: lenalidomide; Assigned to Arm(s): lenalidomide
B: Arm Label: 1 (PG - NM (MCH) 0.02%); Type: ACTIVE_COMPARATOR; Interventions: Drug: mechlorethamine-MCH (nitrogen mustard) | Arm Label: 2 (AP - MCH(NM) 0.02%); Type: ACTIVE_COMPARATOR; Interventions: Drug: mechlorethamine-MCH (nitrogen mustard) | Intervention Type: DRUG; Name: mechlorethamine-MCH (nitrogen mustard); Assigned to Arm(s): 1 (PG - NM (MCH) 0.02%), 2 (AP - MCH(NM) 0.02%)
C: Arm Label: Brentuximab vedotin; Type: EXPERIMENTAL; Interventions: Drug: Brentuximab vedotin | Intervention Type: DRUG; Name: Brentuximab vedotin; Assigned to Arm(s): Brentuximab vedotin
D: Arm Label: Caelyx; Type: EXPERIMENTAL; Interventions: Drug: pegylated liposomal doxorubicin hydrochloride | Intervention Type: DRUG; Name: pegylated liposomal doxorubicin hydrochloride; Assigned to Arm(s): Caelyx

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nevirapine (NVP) Use to Prevent Maternal-Infant HIV Transmission: A Randomized Clinical Trial of Two Doses of NVP Compared to Six Weeks of NVP for the Prevention of Maternal-Infant HIV Transmission in the Breastfeeding Infant
Brief Summary: HIV can be transmitted from an HIV infected mother to her infant through her breast milk. The purpose of this study is to determine whether giving infants of HIV infected mothers the anti-HIV drug nevirapine (NVP) for six weeks will reduce the risk of HIV transmission.

Study hypothesis: Six weeks of nevirapine prophylaxis provided to the infant will decrease HIV transmission through breastfeeding.


Options:
A: Arm Label: 2A; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine | Arm Label: 2B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nevirapine placebo | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): 2A | Intervention Type: DRUG; Name: Nevirapine placebo; Assigned to Arm(s): 2B
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nevirapine and mulitvitamins | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine and mulitvitamins | Intervention Type: DRUG; Name: Nevirapine and mulitvitamins; Assigned to Arm(s): 1, 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nevirapine placebo | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Nevirapine placebo; Assigned to Arm(s): 2
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nevirapine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine, Drug: HIV immune globulin solution | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): 1, 2, 3 | Intervention Type: DRUG; Name: HIV immune globulin solution; Assigned to Arm(s): 3

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nevirapine (NVP) Use to Prevent Maternal-Infant HIV Transmission: A Randomized Clinical Trial of Two Doses of NVP Compared to Six Weeks of NVP for the Prevention of Maternal-Infant HIV Transmission in the Breastfeeding Infant
Brief Summary: HIV can be transmitted from an HIV infected mother to her infant through her breast milk. The purpose of this study is to determine whether giving infants of HIV infected mothers the anti-HIV drug nevirapine (NVP) for six weeks will reduce the risk of HIV transmission.

Study hypothesis: Six weeks of nevirapine prophylaxis provided to the infant will decrease HIV transmission through breastfeeding.


Options:
A: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nevirapine, Drug: AZT, Drug: NVP and AZT | Arm Label: C; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine, Drug: AZT, Drug: NVP+AZT | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine, Drug: NVP | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: AZT; Assigned to Arm(s): A, C | Intervention Type: DRUG; Name: NVP and AZT; Assigned to Arm(s): A | Intervention Type: DRUG; Name: NVP; Assigned to Arm(s): B | Intervention Type: DRUG; Name: NVP+AZT; Assigned to Arm(s): C
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nevirapine and mulitvitamins | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine and mulitvitamins | Intervention Type: DRUG; Name: Nevirapine and mulitvitamins; Assigned to Arm(s): 1, 2
C: Arm Label: maternal nevirapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nevirapine | Arm Label: maternal placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: No intervention | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): maternal nevirapine | Intervention Type: DRUG; Name: No intervention; Assigned to Arm(s): maternal placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Nevirapine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Nevirapine placebo | Intervention Type: DRUG; Name: Nevirapine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Nevirapine placebo; Assigned to Arm(s): 2

Answer: D